- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoProblem 8 What is \(|-42|\), simplified? ... [FREE SOLUTION]POS1207 AMELIORATION OF RHEUMATOID ARTHRITIS IN PREGNANCY IS NOT ASSOCIATED WITH ENHANCED FUNCTION OF REGULATORY T CELLSPOS1513-HPR THE USE OF SUPRAMAXIMAL VERIFICATION TESTING FOR DETERMINING A ‘TRUE’ MAXIMAL EFFORT DURING CARDIOPULMONARY EXERCISE TESTING IN PEOPLE WITH RHEUMATOID ARTHRITIS AND PHYSICALLY INACTIVE NON-RA CONTROLS - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Poster Tours
Clinical Poster Tours: Clinical aspects of small vessel vasculitis - Part 1
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY
- J. W. Park1,
- Y. K. Kim1,
- J. R. Curtis2,
- S. R. Choi3,
- J. N. Yeo4,
- M. J. Kim5,
- Y. J. Lee1,3,
- E. B. Lee1,6
- 1Seoul National University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)
- 2University of Alabama at Birmingham, Division of Clinical Immunology & Rheumatology, Birmingham, AL, United States of America
- 3Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seongnam-si, Korea, Rep. of (South Korea)
- 4Gachon University Gil Medical Center, Division of Rheumatology, Department of Internal Medicine, Incheon, Korea, Rep. of (South Korea)
- 5Seoul Metropolitan Government - Seoul National University, Boramae Medical Center, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)
- 6Seoul National University, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul, Korea, Rep. of (South Korea)
Abstract
Background: Infection is a major cause of mortality within the first year of induction therapy in patients with ANCA-associated vasculitis (AAV). A recent EULAR AAV guideline recommends the prophylactic use of trimethoprim-sulfamethoxazole (TMP-SMX) against Pneumocystis jirovecii pneumonia (PJP) and other infections. However, while a limited number of studies have suggested an association between prophylactic TMP-SMX and lower incidence of serious infections, this relationship has not been thoroughly investigated in a large-scale real-world cohort.
Objectives: We aimed to investigate the impact of TMP-SMX in preventing serious infection in patients with AAV receiving either rituximab (RTX) or cyclophosphamide (CYC).
Methods: This multicenter cohort study included patients with AAV treated with either RTX or CYC for induction therapy in three referral hospitals in South Korea. A total of 280 patients were analyzed. The date when RTX or CYC was administered was set as the index date. Then, the patients were divided into TMP-SMX group (n=230) and control group (n=50) according to whether they received TMP-SMX during 28 days from the index date, which was set as a lead-in period. Primary outcome of this study was 1-year incidence of serious infections, which was defined as requiring IV antibiotic treatment, hospitalization or prolongation of hospitalization. The hazard ratio of serious infection was estimated using Cox proportional hazard model. Additionally, the impact of prophylaxis was also analyzed stratified by various clinical factors.
Results: Over 209.8 person-years in the entire cohort, 60 serious infections occurred, with a 1-year mortality rate of 18.3%. The incidence rate of serious infection (per 100 person-years) was 26.2 and 42.7 in the TMP-SMX group and the control group, respectively. The most common source of infection was respiratory tract (n = 31, 51.7%), followed by gastrointestinal (n = 8, 13.3%) and genitourinary tract (n = 8, 13.3%). There were 4 PJP cases, 1 in the TMP-SMX group and 3 in the control group. Most serious infections (68.3%) occurred during the first 90 days. Overall, prophylactic TMP-SMX significantly reduced the incidence of serious infections (adjusted hazard ratio (HR) 0.39 [0.28-0.54]). Time-varying Cox regression showed that the benefit of prophylactic TMP-SMX was evident during the first 90-day period (adjusted HR 0.32 [0.24-0.44]) but was not significant afterward (Figure 1). The prophylactic impact of TMP-SMX was also significant in serious infection except PJP and viral infection (adjusted HR 0.59 [0.39-0.91]). In the subgroup analysis, the impact of prophylactic TMP-SMX was more prominent in the presence of baseline lymphopenia (defined as lymphocyte count < 800/µL), azotemia (defined as estimated GFR < 60mL/min/1.73m2), or in patients with microscopic polyangiitis. Other clinical factors such as patient’s age, baseline BVAS, lung involvement, and concomitant steroid pulse treatment did not show a significant interaction with the effect of TMP-SMX (Figure 2).
Conclusion: Prophylactic TMP-SMX significantly reduces the 1-year incidence of serious infection in patients with AAV undergoing induction therapy with CYC or RTX. However, this additional benefit is evident primarily during the initial period following induction therapy.
- Download figure
- Open in new tab
- Download powerpoint
Figure 1.
Kaplan-Meier curves indicating the prophylactic effect of TMP-SMX on serious infection using time-varying cox regression. TMP-SMX significantly reduced the incidence of serious infection in the first 90-day period (aHR=0.32 [0.24-0.44]), however was insignificant afterward (aHR=0.75 [0.38-1.46]).
- Download figure
- Open in new tab
- Download powerpoint
Figure 2.
Forest plot indicating the impact of TMP-SMX stratified by various clinical factors
REFERENCES: NIL.
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- Observational studies/ registry
- Real-world evidence
- Prognostic factors
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Observational studies/ registry
- Real-world evidence
- Prognostic factors
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens